Certara (CERT) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
11 May, 2026Executive summary
Q1 2026 revenue grew 1% year-over-year to $106.9 million, driven by 7% software growth and a 4% decline in services revenue.
Net loss was $8.8 million, compared to net income of $4.7 million in Q1 2025, due to higher operating expenses and tax costs.
Completed divestiture of the Regulatory and Medical Writing business for up to $135 million, shifting revenue mix closer to 50/50 software and services.
Strategic actions included reorganizing into MID3 and ACE, formalizing AI leadership, and partnerships with NVIDIA and Altasciences.
Appointed Chief AI Officer and accelerated enterprise-wide AI initiatives.
Financial highlights
Software revenue was $49.7 million (+7%); services revenue was $57.2 million (–4%).
Software bookings rose 20% to $48.7 million; services bookings fell 14% to $66.6 million.
Adjusted EBITDA was $31.7 million (margin ~30%), down from $34.8 million last year.
Adjusted net income was $14.5 million, down from $22.2 million in Q1 2025.
Diluted loss per share was $0.06; adjusted diluted EPS was $0.09, down from $0.14.
Cash and equivalents at quarter end were $149.5 million; term loan borrowings were $294.8 million.
Outlook and guidance
2026 full-year revenue expected at $395–$405 million, including $18 million from divested business.
Excluding divestiture, full-year growth projected at 0–4%, with stronger growth in the second half.
Adjusted EBITDA margin guided at 30–32%; adjusted EPS expected at $0.35–$0.41; fully diluted shares at 157–159 million.
Latest events from Certara
- FY 2025 revenue rose 9% to $418.8M; 2026 outlook is flat to 4% growth with a new CEO.CERT
Q4 20259 Apr 2026 - Director elections, auditor ratification, and executive pay are key 2026 meeting topics.CERT
Proxy filing3 Apr 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.CERT
Proxy filing3 Apr 2026 - AI-driven product launches and disciplined cost control set the stage for cautious 2026 growth.CERT
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - 2026 guidance reflects stable markets, strong biosimulation growth, and operational transformation.CERT
Leerink Global Healthcare Conference 20269 Mar 2026 - Operational rigor, AI innovation, and cloud migration drive growth amid evolving regulatory and market dynamics.CERT
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Strong biotech demand, AI-driven innovation, and cloud adoption fuel growth amid regulatory shifts.CERT
Stephens Annual Investment Conference3 Feb 2026 - Q2 revenue up 3% to $93.3M, net loss $12.6M, guidance reiterated at $385M–$400M.CERT
Q2 20242 Feb 2026 - Biosimulation and AI adoption accelerate, supported by acquisitions and a unified cloud platform.CERT
Jefferies Global Healthcare Conference1 Feb 2026